HeartSciences Inc(HSCS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.91 | Insider Own | 20.43% | Shs Outstand | 3.2M | Perf Week | 16.61% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 29.01% | Insider Trans | - | Shs Float | 3.1M | Perf Month | 71.22% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.72 | Inst Own | 3.94% | Short Float | 1.63% | Perf Quarter | 86.7% |
| Income | -0.01B | P/S | - | EPS this Y | 21.08% | Inst Trans | -7.83% | Short Ratio | 0.02 | Perf Half Y | 38.19% |
| Sales | 0.00B | P/B | 49.71 | EPS next 5Y | - | ROA | -192.75% | Short Interest | 0.05M | Perf YTD | 13.59% |
| Book/sh | 0.07 | P/C | 8.25 | EPS past 3/5Y | 64.81% 32.51% | ROE | -4239.9% | 52W High | -19.31% ($4.35) | Perf Year | 6.04% |
| Cash/sh | 0.43 | P/FCF | - | Sales past 3/5Y | -5.7% -29.95% | ROIC | -2276.58% | 52W Low | 115.34% ($1.63) | Perf 3Y | -95.44% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 58.2% | Gross Margin | -2982.15% | Volatility(W/M) | 12.98% 10.95% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -0.71% | Oper. Margin | -194787.38% | ATR (14) | 0.36 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.37 | EPS Q/Q | 54.12% | Profit Margin | -211666.47% | RSI (14) | 60.98 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.5 | Sales Q/Q | -100% | SMA20 | 18.39% ($2.96) | Beta | 1.77 | Target Price | $12 |
| Payout | - | Debt/Eq | 17.13 | Earnings | 2026/07/22 | SMA50 | 32.74% ($2.64) | Rel Volume | 0.1 | Prev Close | $4.12 |
| Employees | 14 | LT Debt/Eq | 0.78 | EPS/Sales Surpr. | 22.73% - | SMA200 | 38.34% ($2.54) | Avg Volume(3M) | 2.31M | Price | $3.51 |
| IPO | 2022/6/15 | Option/Short | No/Yes | Trades | 765 | Volume | 221,158 | Change | -14.81% |
Company
HSCS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
HeartSciences() is a medical device company headquartered in Southlake, Texas, USA. It develops MyoVista wavECG, an AI-based electrocardiogram (ECG) diagnostic technology. The company combines a standard 12-lead ECG with a neural network algorithm to help detect cardiac functional abnormalities such as heart failure at an early stage, and it operates as a micro-cap healthcare company.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
HSCS has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +21.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by -95.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 3.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $14M.
HSCS $14M PER -
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is HSCS?
HSCS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of HSCS?
The market cap of HSCS is approximately $14M, ranking 5,424 within its sector.
What is the 52-week high and low for HSCS?
HSCS has recorded a 52-week high of $4.35 and a low of $1.63.
